Olalekan “Lekan” Ajayi, PharmD, MBA, is oncology service line manager at Sheridan Memorial Hospital in Sheridan, Wyoming. In this role, Dr. Ajayi oversees both strategic and operational initiatives of the oncology and internal medicine programs. He has also worked extensively as a clinical pharmacist and an oncology pharmacy manager for eight years.
Dr. Ajayi currently serves on the ACCC Board of Trustees and has worked on a number of ACCC initiatives.
He is passionate about patient access to quality cancer care in rural communities. Specifically, Dr. Ajayi is interested in expanding patient access to oncology clinical trials and is working with ACCC on ways to overcome the challenges of patient accruals for clinical trials in rural cancer programs.
He holds a Doctor of Pharmacy degree from the University of Wyoming, and a Master’s in Business Administration from the University of Colorado, Denver.
In addition, Melody provides guidance on pharmacy clean-room design, ensuring that the pharmacy is in compliance with regulatory requirements.
Melody currently serves as pharmacist liaison to the Florida Society of Clinical Oncology (FLASCO) Board of Directors.
Jorge J. García, PharmD, MS, MHA, MBA, FACHE, serves as an assistant vice president at Baptist Health South Florida with responsibility for system-wide oncology pharmacy services primarily at the Miami Cancer Institute, the Lynn Cancer Institute, and inpatient oncology pharmacy services at several acute hospitals. Dr. García has pioneered pharmacy charge integrity and revenue management in the health-system setting and is a thought leader and national speaker in this area, as well as in the areas of alternative payment models, biosimilars, and value-based oncology care. Dr. García leads advocacy efforts at the national level to promote evaluation of safe and effective use of biosimilars, along with stakeholder engagement to support a more just and sustainable biosimilar pharmacoeconomics model.
Dr. García obtained his Doctor of Pharmacy and MBA from Nova Southeastern University in 2010. He then transitioned to the University of Pittsburgh Medical Center to pursue an ASHP-accredited PGY-1 & PGY-2 Health-System Pharmacy Administration Residency and a Master of Science in Pharmacy Administration. He also completed an MHA from Florida Atlantic University. Dr. García is a board member at the Florida Society of Clinical Oncology (FLASCO), a recipient of the FLASCO 2018 Above and Beyond Award, and a fellow of the American College of Healthcare Executives.
Ali McBride, PharmD, MS, BCOP, is the Clinical Coordinator of Hematology/Oncology at The University of Arizona Cancer Center. Currently serving on the Board of the Association of Community Cancer Centers (ACCC), Dr. McBride also chairs the Awards Selection Committee as well as the Corporate Development Committee. In addition to being a long-time ACCC member, Dr. McBride has been actively involved with the American Society of Health-System Pharmacists (ASHP) and the Hematology/Oncology Pharmacy Association (HOPA).
Dr. McBride has been working on oncology drug shortages and has testified on behalf of HOPA at the U.S. Food and Drug Administration (FDA) Drug Shortage Workshop; presented on behalf of ACCC at the Washington, D.C., Congressional Session; and was an invited member of the ASHP Drug Shortage Stakeholders Meeting. Dr. McBride is also actively involved with biosimilar regulation and the pharmacoeconomic impact of biosimilars into the U.S. marketplace. He currently serves as a working group member for HOPA on its biosimilar committee. In addition, he serves on the National Quality Forum Cancer Standing Committee. He has published numerous articles on drug shortages, oral chemotherapy adherence, stem cell transplant, and biosimilar implementation into the U.S. healthcare market.
Sandeep Parsad, PharmD, MBA, BCOP, is the assistant director of pharmacy at the University of Chicago Medicine. She is the director of the PGY2 oncology pharmacy residency program, co-chair of the Oncology Drug Safety Committee, and oversees hematology/oncology and investigational drug services.
Dr. Parsad has a strong interest in stem cell transplantation, hematologic malignancies, value-based payment models, and oncology quality initiatives.